Evidence map›Paper›PMID 29408860›Full record

ArticlePloS one2018

Human cytomegalovirus epidemiology and relationship to tuberculosis and cardiovascular disease risk factors in a rural Ugandan cohort.

Lisa Stockdale, Stephen Nash, Angela Nalwoga, Hannah Painter, Gershim Asiki, Helen Fletcher, Robert Newton

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Does cytomegalovirus infection increase the risk of tuberculosis in UK children?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Observational
  7. Quantitative measures of humanPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Prevention ofPharmaceutics · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Lisa StockdaleLondon School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, London, United Kingdom.ORCID 0000-0002-2576-8783
Stephen NashLondon School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London, United Kingdom.
Angela NalwogaLondon School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, London, United Kingdom.
Hannah PainterLondon School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, London, United Kingdom.
Gershim AsikiMedical Research Council/Uganda Virus Research Institute, Entebbe, Uganda.
Helen FletcherLondon School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, London, United Kingdom.
Robert NewtonMedical Research Council/Uganda Virus Research Institute, Entebbe, Uganda.
London School of Hygiene & Tropical Medicine · GBCentre international de recherche sur le cancer · FRUganda Virus Research Institute · UG

Funding

Medical Research Council MR/K012126/1World Health Organization 001
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) infection has been associated with increased mortality, specifically cardiovascular disease (CVD), in high-income countries (HICs). There is a paucity of data in low- and middle-income countries (LMICs) where HCMV seropositivity is higher. Serum samples from 2,174 Ugandan individuals were investigated for HCMV antibodies and data linked to demographic information, co-infections and a variety of CVD measurements. HCMV seropositivity was 83% by one year of age, increasing to 95% by five years. Female sex, HIV positivity and active pulmonary tuberculosis (TB) were associated with an increase in HCMV IgG levels in adjusted analyses. There was no evidence of any associations with risk factors for CVD after adjusting for age and sex. HCMV infection is ubiquitous in this rural Ugandan cohort from a young age. The association between TB disease and high HCMV IgG levels merits further research. Known CVD risk factors do not appear to be associated with higher HCMV antibody levels in this Ugandan cohort.

Indexed as

Rural PopulationAdolescentAdultAgedAged, 80 and overAntibodies, ViralCardiovascular DiseasesChildChild, PreschoolCohort StudiesCytomegalovirusCytomegalovirus InfectionsFemaleHumansImmunoglobulin GInfantAntibodies, ViralImmunoglobulin G

Identifiers

PMID29408860
PMCPMC5800673
OpenAlexW2790476146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.